Chembio Diagnostics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume364,635 shs
Average Volume3.32 million shs
Market Capitalization$65.59 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Chembio Diagnostics logo

About Chembio Diagnostics

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.27 out of 5 stars

Medical Sector

899th out of 2,099 stocks

Pharmaceutical Preparations Industry

435th out of 830 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

Is Chembio Diagnostics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Chembio Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CEMI, but not buy additional shares or sell existing shares.
View analyst ratings for Chembio Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Chembio Diagnostics?

Wall Street analysts have given Chembio Diagnostics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chembio Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Chembio Diagnostics

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its quarterly earnings data on Thursday, May, 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. The firm had revenue of $8.72 million for the quarter. Chembio Diagnostics had a negative net margin of 72.88% and a negative trailing twelve-month return on equity of 79.63%.
View Chembio Diagnostics' earnings history

How has Chembio Diagnostics' stock price been impacted by COVID-19 (Coronavirus)?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CEMI shares have increased by 4.5% and is now trading at $3.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CEMI?

5 brokers have issued 12 month target prices for Chembio Diagnostics' stock. Their forecasts range from $4.00 to $10.00. On average, they expect Chembio Diagnostics' share price to reach $7.25 in the next year. This suggests a possible upside of 123.8% from the stock's current price.
View analysts' price targets for Chembio Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:
  • Mr. Richard L. Eberly, Pres, CEO & Director (Age 60, Pay $556.03k)
  • Mr. Neil A. Goldman, Exec. VP, CFO & Sec. (Age 53, Pay $469.93k)
  • Mr. Javan Esfandiari, Exec. VP and Chief Science & Technology Officer (Age 54, Pay $557.52k)
  • Mr. Paul J. Angelico, VP of Global Operations
  • Mr. Charles Caso, VP of Sales & Marketing
  • Dr. Konstantin Lyashchenko, Research Director of Chembio Diagnostic Systems Inc

Who are some of Chembio Diagnostics' key competitors?

What other stocks do shareholders of Chembio Diagnostics own?

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.24%), Penbrook Management LLC (1.72%), Geode Capital Management LLC (1.49%), Perkins Capital Management Inc. (1.44%), Northern Trust Corp (1.21%) and Penbrook Management LLC (1.04%).
View institutional ownership trends for Chembio Diagnostics

Which major investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including Friess Associates LLC, Union Square Park Capital Management LLC, Goldman Sachs Group Inc., Penbrook Management LLC, Northern Trust Corp, HighTower Advisors LLC, Trexquant Investment LP, and Morgan Stanley.
View insider buying and selling activity for Chembio Diagnostics
or view top insider-selling stocks.

Which major investors are buying Chembio Diagnostics stock?

CEMI stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Renaissance Technologies LLC, JPMorgan Chase & Co., BlackRock Inc., Geode Capital Management LLC, PDT Partners LLC, Millennium Management LLC, and Jane Street Group LLC.
View insider buying and selling activity for Chembio Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $3.24.

How much money does Chembio Diagnostics make?

Chembio Diagnostics has a market capitalization of $65.59 million and generates $32.47 million in revenue each year. The company earns $-25,520,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

How many employees does Chembio Diagnostics have?

Chembio Diagnostics employs 355 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is

Where are Chembio Diagnostics' headquarters?

Chembio Diagnostics is headquartered at 555 WIRELESS BLVD., HAUPPAUGE NY, 11788.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.